Pune, India -- (SBWIRE) -- 05/25/2018 -- The Global Liver Biopsy Market is estimated to show significant growth with a CAGR of ~4.2% during the forecast period 2018-2023.

Liver Biopsy is a process of obtaining a small piece of liver by a small surgical needle for further diagnostic tests. This test is done to check for Liver cirrhosis, cancer, non-alcoholic fatty liver disease, chronic hepatitis B or C, and autoimmune hepatitis. The most common type of liver biopsy practised is percutaneous liver biopsy which involves inserting a needle through your abdomen into the liver and removing a small piece of tissue. Two other types of liver biopsy are transjugular in which a vein in the neck is used and (laparoscopic) method uses a small abdominal incision to remove liver tissue with a needle.

With the increasing addiction to alcohol and drugs, prevalence of liver diseases have increased. With the rising prevalence of liver diseases, growth in medical technology, availability of diagnostic methods, favourable reimbursement and insurance policies are accelerating the market growth. Whereas, high expense of this test, availability of other non-invasive tests like fluoroscopy, contrast ultrasound and other blood tests for diagnosis of liver disease and side effects associated with liver biopsy test such as Intrahepatic hematoma, Bacterimia, Fever and Dizziness are hindering the market growth.

Liver Biopsy Market - Key Players

Some of key the players in the market are Becton, Dickinson and Company, MDxHealth, Veran medical, Medtronic, Argon Medical Devices, Inc., Mauna Kea Technologies, Boston Scientific Corporation, Intact Medical Corp., C. R. Bard, Inc., Leica Biosystems, Cook Medical, RI.MOS., Hologic, Inc., Sterylab, INRAD Inc., Fujifilm Medical Systems, and others.

Liver Biopsy Market - Competitive Analysis

Medtronic headquartered in Ireland has been solving healthcare challenges with its innovative solutions for more than half a century. Medtronic acquired Coviden In 2015 and reshaped its business structure in Medical devices. In year 2015, Medtronic launched SharkCore™ FNB needle which is a pioneering development in the Fine Needle Biopsy market for diagnosis of cancerous tumours adjacent to the GI tract, and benign liver tissue. This product showed five times increased sales than the other two products Beacon™ FNF Needle and Beacon™ FNA Exchange System.

Boston Scientific Corporation with its eminent team of R&D professionals has been a top pharmaceutical with a huge global presence since 1979. This company launched Acquire Endoscopic Ultrasound Fine Needle Biopsy (FNB) Device, initially in May 2016 and was in full launch in January 2017. The Acquire Fine Needle Biopsy Device is designed to sample targeted tissue sample from liver, pancreas and stomach through the accessory channel of a curvilinear echoendoscope. EUS guided liver biopsy is a newer approach for performing liver biopsy as it is efficient and provides adequate diagnostic tissue for histological evaluation. This reason has made the product gain popularity among gastroenterologists and hepatologists. Apart from this product Boston Scientific Corporation has two more products namely Expect Slimline (SL) endoscopic ultrasound aspiration needle and Expect™19ga Flex Needle used in liver biopsy

Click to Get Sample Report @ https://www.marketresearchfuture.com/sample_request/5534 .

Liver Biopsy Market - Segmentation

The Global Liver Biopsy Market is segmented on the basis of type, indication, and end user.

On the basis of the diagnosis, it is segmented into percutaneous, transjugular, and laparoscopic biopsy.

On the basis of indication, it is segmented into nonalcoholic fatty liver disease, chronic hepatitis B or C, autoimmune hepatitis, alcoholic liver disease, and others.

Based on the end user, it is segmented into hospitals & clinics, tertiary care centers, urology centers, and others.

Liver Biopsy Market - Regional Analysis

North America is anticipated to lead the global Liver Biopsy Market owing to high prevalence of liver diseases, increasing obese population, rising number of fast food chains, addiction to alcohol and drugs increasing acceptance of new technologies, presence of key pharmaceutical companies and rising health awareness. Additionally, liver disease is one of the major cause of mortality and morbidity in the Americas, thus boosting the market growth. For Instance, according to the data from (CDC), in 2016, 38,170 deaths occurred due to liver diseases in the U.S. and 6.10% of the adults were diagnosed with liver diseases in the U.S. alone.

Europe has the second largest market in the global liver biopsy market. In Europe, Germany, France, and the U.K are the major markets for liver biopsy According to the Lancet Liver Campaign report on liver diseases in the U.K., liver disease has most incidence of death, which is expected to increase shortly. It is also stated that alcohol abuse is one of the major cause of various liver diseases among the adults. The European market is expected to exhibit extensive growth during the forecast period due to, the growing research and developments sector, need for advanced treatments along with growing need for better healthcare infrastructure, rising cases of alcoholic fatty liver disease, various government legislative reforms providing regulatory guidelines to manufacturing companies and flourishing medical device market attributed to the presence of key pharmaceutical companies in this region.

Get Discount on Report @ https://www.marketresearchfuture.com/check-discount/5534 .

Asia Pacific is predicted to be the fastest region in the global liver biopsy market. Country like China, Singapore, Malaysia ,Australia of Asia Pacific region are considering fastest growing region due to the presence of huge population suffering with liver cirrhosis, fatty liver diseases and Hepatitis B&C.. These countries are quickly adapting to new technologies so as to improve the health of every citizen. The government is also supporting the same by investing in research and development in clinical research sector as well as in building proper healthcare infrastructure. Asia Pacific region has the highest opportunity of growth because of increase in hepatitis diseases as well as rising healthcare infrastructure. For instance according to WHO report on global hepatitis Western pacific region has the highest incidence of hepatitis.

The Middle East & Africa holds the least share in the market owing to the presence of low income countries and low healthcare expenditure, especially within the African region. However the market is expected to grow slowly due to presence of developed countries like Saudi Arabia and United Arab of Emirates and increasing patient pool of Hepatitis B&C.

Major Table of Content

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

Continued….

List of Tables

Table 1 Liver Biopsy Industry Synopsis, 2017-2023

Table 2 Global Liver Biopsy Market Estimates and Forecast, 2017-2023, (USD Million)

Table 3 Global Liver Biopsy Market by Region, 2017-2023, (USD Million)

List of Figures

Figure 1 Research Process

Figure 2 Segmentation for Global Liver Biopsy Market

Figure 3 Segmentation Market Dynamics for Liver Biopsy Market

To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/5534 .

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.